Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931818 | 0.83 | BCHE (0.46) | RAB9ANPC1CPB2MAPTTSHR | |
| SCHEMBL12964548 | 0.83 | BCHE (0.46) | RAB9ANPC1CPB2MAPTTSHR | |
| SCHEMBL22230134 | 0.82 | HCAR3 (0.49) | PCSK9HCAR3HCAR2RAB9ANPC1 | |
| SCHEMBL22241695 | 0.81 | PCSK9 (0.62) | PCSK9RAB9ANPC1CPB2 | |
| SCHEMBL21564563 | 0.81 | STK17B (0.53) | RAB9ANPC1CPB2 | |
| SCHEMBL30931847 | 0.81 | STK17B (0.53) | RAB9ANPC1CPB2 | |
| SCHEMBL29775946 | 0.80 | PCSK9 (0.56) | PCSK9RAB9A | |
| SCHEMBL22241655 | 0.80 | PCSK9 (0.56) | PCSK9RAB9A | |
| SCHEMBL22242653 | 0.78 | PCSK9 (0.58) | PCSK9AAK1HCAR3HCAR2CPB2 | |
| SCHEMBL22241701 | 0.78 | PCSK9 (0.49) | PCSK9CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| EP-4470609-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2024-12-04 | — | — | EP | disclosed |
| EP-3911648-B1 | 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-10-23 | — | — | EP | disclosed |
| US-20230407285-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2023-03-14 | — | — | US | disclosed |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2022-02-15 | — | — | US | disclosed |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-09-17 | — | — | US | disclosed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248001-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | PCSK9 1/4885AAK1 2023/4885HCAR3 1426/4885 |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | PCSK9 1/4885AAK1 2100/4885HCAR3 886/4885 |
| US-20230407285-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | PCSK9 1/4885AAK1 1841/4885HCAR3 714/4885 |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | PCSK9 1/4885AAK1 2316/4885HCAR3 812/4885 |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | PCSK9 1/4885AAK1 1841/4885HCAR3 714/4885 |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, LDLR, PCSK7 | PCSK9 1/4885AAK1 2513/4885HCAR3 3362/4885 |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | PCSK9 1/4885AAK1 2100/4885HCAR3 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.